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abstract
PURPOSE This study investigates whether focal boosting of the macroscopic visible tumor with external beam
radiotherapy increases biochemical disease-free survival (bDFS) in patients with localized prostate cancer.
PATIENTS AND METHODS In the phase III, multicenter, randomized controlled Focal Lesion Ablative Microboost
in Prostate Cancer trial, 571 patients with intermediate- and high-risk prostate cancer were enrolled between
2009 and 2015. Patients assigned to standard treatment received 77 Gy (fractions of 2.2 Gy) to the entire
prostate. The focal boost arm received an additional simultaneous integrated focal boost up to 95 Gy (fractions
up to 2.7 Gy) to the intraprostatic lesion visible on multiparametric magnetic resonance imaging. Organ at risk
constraints were prioritized over the focal boost dose. The primary end point was 5-year bDFS. Secondary end
points were disease-free survival (DFS), distant metastases-free survival, prostate cancer-specific survival,
overall survival, toxicity, and health-related quality of life.
RESULTS Median follow-up was 72 months. Biochemical DFS was significantly higher in the focal boost
compared with the standard arm (hazard ratio 0.45, 95% CI, 0.28 to 0.71, P, .001). At 5-year follow-up bDFS
was 92% and 85%, respectively. We did not observe differences in prostate cancer-specific survival (P 5 .49)
and overall survival (P5 .50). The cumulative incidence of late genitourinary and GI toxicity grade$ 2 was 23%
and 12% in the standard arm versus 28% and 13% in the focal boost arm, respectively. Both for late toxicity as
health-related quality of life, differences were small and not statistically significant.
CONCLUSION The addition of a focal boost to the intraprostatic lesion improved bDFS for patients with localized
intermediate- and high-risk prostate cancer without impacting toxicity and quality of life. The Focal Lesion
Ablative Microboost in Prostate Cancer study shows that a high focal boost strategy to improve tumor control
while respecting organ at risk dose constraints is effective and safe.
J Clin Oncol 39:787-796. © 2021 by American Society of Clinical Oncology
INTRODUCTION
A dose-response relationship has been described
for external beam radiotherapy (EBRT) for localized
prostate cancer. Whole-gland dose escalation up to
80 Gy is considered effective and safe.1–4 Further
increase in dose to the entire prostate results in
higher toxicity rates.2,5–7
Local recurrences of prostate cancer following radiother-
apy often originate from the primary tumor site.8 Therefore,
focal boosting has been proposed to increase biochemical
disease-free survival (bDFS) without increasing toxicity.9
The dose to the macroscopic visible tumor on multi-
parametric magnetic resonance imaging (mpMRI) is in-
creased without increasing the dose to the organs at risk
(OAR). A systematic review identified 13 single-arm
studies that assessed the efficacy and safety of a focal
boost using EBRT, low–dose-rate brachytherapy (BT), or
high–dose-rateBT. Thepooledmedian5-year bDFSof the
13 studies was 85% (range, 79%-100%).10
To test the hypothesis that focal dose escalation improves
bDFS in intermediate- and high-risk prostate cancer, the
Focal Lesion Ablative Microboost in Prostate Cancer
(FLAME) trial was conducted, comparing EBRT of 77 Gy
in 35 fractions with or without a simultaneous integrated
focal boost up to 95 Gy.11 As the benefit of focal boosting
was unproven, the trial was designed deliberately to avoid
additional toxicity by the focal boost. Therefore, pre-
specified dose constraints to OAR were strictly adhered
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PATIENTS AND METHODS
Study Design
The multicenter, phase III, randomized controlled FLAME
trial was carried out in the University Medical Center (UMC)
Utrecht, the Netherlands Cancer Institute in Amsterdam, the
Radboudumc in Nijmegen in the Netherlands, and the
niversity Hospitals Leuven in Belgium. The research Protocol
was approved by the medical ethics committee of the UMC
Utrecht (NL26038.041.08) for the Netherlands and Uni-
versity Hospitals Leuven for Belgium (B322201110225).
The FLAME study has been registered (ClincalTrials.gov
identifier: NCT01168479).
Participants
Since 2009, patients with intermediate- and high-risk lo-
calized prostate cancer were included according to the Ash
criteria.12 Since the Ash criteria are no longer in use in
today’s practice, we used the European Association of
Urology risk classification13 for further analyses.
Exclusion criteria were as follows: WHO performance
score . 2, International Prostate Symptom score $ 20,
evidence of lymph node involvement or distant metastases,
a history of pelvic radiation, prostatectomy, transurethral
resection of the prostate (TURP) less than 3 months before
radiotherapy, and patients who were not able to undergo
MRI. All included patients provided written informed
consent.
Random Assignment and Masking
The patients were randomly assigned in a 1:1 ratio to the
standard or focal boost arm. Random assignment and
stratification took place by an independent trial center at
the UMC Utrecht, with a minimization procedure using the
center as a minimization factor, ensuring balance within
each stratum and overall balance. Contrary to what was
intended in the trial Protocol, hormonal therapy and TURP
were not used as minimization factors. Nonetheless, post
hoc stratification for hormonal therapy and TURP showed
well-balanced groups (Data Supplement, online only). The
FLAME trial was blinded for patients; blinding for the in-
vestigator was not possible as the treating physicians were
involved in the radiotherapy planning.
Procedures
Patients randomly assigned to the standard treatment arm
received conventionally fractionated EBRT consisting of
77 Gy in 35 fractions of 2.2 Gy (equivalent dose [EQD2] 81.8
Gy, assuming an a/b ratio of 1.2) to the prostate. Patients
assigned to the focal boost arm additionally received a si-
multaneous integrated focal boost up to 95 Gy to the mac-
roscopic tumor as visible on mpMRI, resulting in 35 fractions
of up to 2.7 Gy (EQD2 115.8 Gy). The boost dose was re-
duced, if required, to meet the OAR constraints. The treat-
ment planning, including dose constraints and achieved dose
escalation, has been described before11,14,15 (Data Supple-
ment). The mpMRI scans were performed in the four par-
ticipating centers. Although the Prostate Imaging Reporting
and Data System (PI-RADS) guidelines were published after
the start of the FLAME trial, the mpMRI protocols were
conformed to the PI-RADS recommendations.16,17 Target
volumes and the OAR were delineated on a planning com-
puted tomography scan and planning mpMRI scan. Intra-
prostatic lesions were contoured as gross tumor volume
(GTV) using T2-weighted, diffusion-weighted imaging and
dynamic contrast-enhanced sequences. One or more
GTV’s could be contoured per patient. The GTV con-
touring has been analyzed before.18 There was no margin
for clinical or planned target volume of the boost. The
seminal vesicles were contoured according to clinical
practice. Elective regional lymph node irradiation was not
performed. Intensity-modulated radiotherapy or volu-
metric modulated arc therapy was applied. Gold fiducial
markers were implanted for position verification during
treatment. (Neo)adjuvant hormonal therapy was pre-
scribed according to clinical practice.
Outcomes
The primary end point was 5-year bDFS, defined as the
time from random assignment to biochemical recurrence.
CONTEXT
Key Objective
Is it possible to improve biochemical disease-free survival by adding a focal boost to the intraprostatic lesion to whole-gland
external beam radiotherapy for patients with intermediate- and high-risk prostate cancer?
Knowledge Generated
A focal boost to the intraprostatic lesion improves biochemical disease-free survival in patients with localized intermediate-
and high-risk prostate cancer. By prioritizing the dose constraints of the organs at risk over the focal boost dose that could
be achieved, toxicity or quality of life did not deteriorate.
Relevance
Addition of a focal boost may be considered for patients treated by external beam radiotherapy for localized intermediate-
and high-risk prostate cancer.
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Biochemical recurrence was defined as the lowest
prostate-specific antigen (PSA) value after treatment (PSA
nadir) plus 2 ng/mL, according to the Phoenix criteria.19
Secondary outcomes were prostate cancer-specific survival
(PCSS), overall survival (OS), toxicity, and health-related
quality of life (HRQoL). Disease-free survival (DFS) and
distant metastases-free survival (DMFS) were described
additionally, with failure defined as biochemical recurrence
and/or evidence of recurrent disease on imaging or time to
the first distant metastasis.
Genitourinary (GU) and GI toxicity were assessed using the
Common Terminology Criteria for Adverse Events version
3.0.20 Toxicity was scored weekly during treatment, at 1,
6 months, and yearly thereafter up to 10 years.
To assess HRQoL, patients filled out the European Orga-
nisation for Research and Treatment of Cancer Quality of
Life Questionnaire-Prostate Cancer Module (prostate-
specific) questionnaire at baseline at 1, 6, 12, 24, and
60 months after treatment.21 Four domains urinary
symptoms, bowel symptoms, sexual activity, and sexual
functioning were addressed. Sexual activity and sexual
functioning are presented for patients who did not receive
hormonal therapy. HRQoL scores ranged from 0 to 100. For
symptom scales (urinary and bowel) higher scores indicate
more symptoms. For functioning scales (sexual activity and
sexual functioning) higher scores indicate better func-
tioning. A difference in scores of more than five points
between treatment arms was considered clinically relevant.
Statistical Analyses
The FLAME trial was designed to have 80% power to detect
a 10% difference in 5-year bDFS between the treatment
arms (alpha 0.05, one-sided). Assuming a 5-year bDFS of
64% in the standard treatment arm,4 we calculated a
sample size including 283 patients per arm.
Primary analyses were performed according to intention-to-
treat. We additionally performed a per protocol analysis.
We performed Kaplan-Meier analyses with log-rank tests up
to 7 years to assess differences in bDFS, DFS, PCSS, and
OS between treatment arms. Patients were censored at the
date of death or last follow-up. Cox regression models were
performed for bDFS, DFS, and DMFS, with adjustment for
center, initial prostate-specific antigen (ng/mL), T-stage,
Gleason, age (years) duration of hormonal treatment
(months), and timing of hormonal treatment (neoadjuvant v
adjuvant). A competing risk analysis according to the Fine
and Gray method was performed, with death by any cause
as a competing risk.22
We created a dose-response curve with the predicted
probability of biochemical and distant metastatic failure up
to 7 years as a function of the near minimum (D98%) dose
to the intraprostatic lesion using logistic regression.
Late toxicity was defined as toxicity from 3 months to 5 years
after the start of treatment. The differences in the cumulative
incidence of late grade $ 2 and late grade $ 3 toxicity
between treatment arms were calculated.
The observed mean HRQoL per domain over time were
graphically presented. Additionally, we performed linear
mixed effect models for repeated measurements to assess
the impact of the focal boost on HRQoL up to 5 years after
treatment, with fixed effects including random assignment
and time as interaction, duration of hormonal therapy, age
and baseline HRQoL, and patient ID as random effect.
Statistical analyses were performed with IBM SPSS Sta-
tistics 25, RStudio and SAS enterprise version 9.4.
RESULTS
BetweenNovember 2009 and February 2015, 571 patients
with intermediate- and high-risk localized prostate cancer
were randomly assigned to the standard treatment (n 5
287) or focal boost arm (n 5 284). All patients had a
potential follow-up of 5 years and median follow-up was
72 months (interquartile range 58-86). Patient and treat-
ment characteristics were well balanced at baseline
[Table 1]). Hormonal treatment was equally distributed
among the study arms (65% in both groups). Themean age
was 70 years (SD 6). Six patients with low-risk disease were
excluded from the analyses as they did not fulfill the in-
clusion criteria (n 5 4 in standard treatment and n 5 2 in
the focal boost arm). Twenty-nine patients (standard
treatment arm n 5 10 and focal boost arm n 5 19) were
excluded from the per protocol analyses because they did
not receive their assigned treatment (Fig 1). Eight patients
(standard treatment [n 5 7], focal boost [n 5 1]) were
excluded from the Kaplan-Meier and Cox regression ana-
lyses because they were not followed up actively.
We observed a 5-year bDFS of 85% (38 events; 95%CI, 80 to
89) in the standard arm and of 92% (21 events; 95%CI, 87 to
94) in the focal boost arm, which were significantly different
between groups (difference: 7%; 95% CI, 4.2 to 9.8). The
Kaplan-Meier curves showed significantly improved bDFS
(log-rank P, .001) and DFS (log-rank P, .001) in the focal
boost arm up to 7 years (Fig 2). DMFS showed no difference
(log-rank P5 .26). We did not find differences in OS (log-rank
P 5 .50) and PCSS (log-rank P 5 .49) (Data Supplement).
Adjusted Cox regression analysis showed that biochemical
failures were reduced by half (hazard ratio [HR] 0.45 [95%CI,
0.29 to 0.71],P, .001), when comparing the focal boost with
standard treatment (Table 2). These analyses showed com-
parable results for DFS (HR 0.48 [95% CI, 0.32 to 0.74], P,
.001), whereas DMFS showed no statistically significant dif-
ference (HR 0.72 [95% CI, 0.43 to 1.22], P5 .22). Adjusted
Cox regression analysis showed an HR of 1.26 (95% CI, 0.83
to 1.92, P5 .27) for OS and 0.69 (95% CI, 0.27 to 1.79, P5
.45) for PCSS. Results of the per protocol analysis did not differ
from the intention-to-treat analysis (Data Supplement). Also,
a competing risk analysis showed similar results (Data
Supplement).
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TABLE 1. Patient and Treatment Characteristics by Randomization Arm
Baseline Standard Treatment Focal Boost Treatment
No. of subjects (n) 287 284
Mean age in years (SD) 70 (7) 70 (6)
Risk stratification (EAU criteria) N (%) N (%)
Low-risk 4 (1) 2 (1)
Intermediate-risk 43 (15) 43 (15)
High-risk 240 (84) 239 (84)
Center N (%) N (%)
UMC Utrecht 160 (56) 160 (56)
NKI 55 (19) 54 (19)
University Hospitals Leuven 47 (16) 46 (16)
Radboudumc 25 (9) 24 (9)
iPSA (ng/mL)
Mean (SD) 15.2 (14.9) 16.3 (13.9)
Clinical T-stage N (%) N (%)
T1c 27 (9) 23 (8)
T2a 29 (10) 28 (10)
T2b 18 (6) 19 (7)
T2c 35 (12) 42 (15)
T3a 124 (43) 111 (39)
T3b 45 (16) 57 (20)
T4 9 (3) 4 (1)
Biopsy Gleason score N (%) N (%)
, 7 55 (19) 47 (17)
7 139 (48) 139 (49)
$ 8 93 (32) 98 (35)
N-stage N (%) N (%)
cN0 226 (79) 231 (81)
pN0 , 10 lymph nodes removed 48 (17) 33 (12)
pN0 $ 10 lymph nodes removed 13 (5) 20 (7)
Timing of hormonal therapy N (%) N (%)
Neoadjuvant hormonal therapy 23 (8) 21 (7)
Adjuvant hormonal therapy 264 (92) 263 (93)
Hormonal therapy prescribed N (%) N (%)
18-36 mo 84 (29) 96 (34)
6-18 mo 32 (11) 33 (12)
6 mo 58 (20) 50 (18)
No 99 (35) 98 (35)
Missing 14 (5) 7 (3)
TURP N (%) N (%)
Yes 41 (14) 36 (13)
No 246 (86) 248 (87)
Cardiovascular disease N (%) N (%)
Yes 155 (54) 147 (52)
No 132 (46) 137 (48)
(continued on following page)
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The biochemical failure rate up to 7 years is presented
as a function of achieved dose to the GTV in Figure 3.
The distant metastases failure rate as a function of GTV
dose is shown in the Data Supplement.
Late GU and GI toxicity grade$ 2 and grade$ 3 differences
were small and not statistically significant between groups.
Cumulative incidences per treatment arm are presented in
Table 3. One patient in the focal boost arm developed grade 4
GU toxicity, 3 years after treatment. He suffered from severe
urinary incontinence for which he underwent a permanent
urinary diversion. No grade 4 GI toxicity occurred.
The response rate was at least 85% in the first year and de-
creased to 55% at 5 years. We did not observe statistically
significant differences in HRQoL domains between both
treatment arms (Data Supplement). Themean (95%CI)HRQoL
per domain per time point is shown in Data Supplement.
TABLE 1. Patient and Treatment Characteristics by Randomization Arm (continued)
Baseline Standard Treatment Focal Boost Treatment
Diabetes mellitus N (%) N (%)
Yes 31 (11) 30 (11)
No 256 (89) 254 (89)
Abbreviations: iPSA, initial prostate-specific antigen; TURP, trans urethral resection of the prostate.
Enrolled
    (N = 571)
Randomly assigned
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     (n = 271)
Did not want to continue   (n = 3)
participation
 Undefinable tumor           (n = 12)
Different dose schedule     (n = 2)
Excluded:
 Low-risk patients                (n = 2)
   Missing outcome data:
 Missing PSA follow-up      (n = 1)
 Missing HRQoL data         (n = 6)
Excluded:
Low-risk patients                (n = 4)
   Missing outcome data:
 Missing PSA follow-up      (n = 7)
 Missing HRQoL data         (n = 5)
Did not finish full schedule          (n = 3)
Different treatments:                    (n = 2)
Concurrent bladder                       (n = 1) 
carcinoma
Nodal disease                                (n = 1) 
FIG 1. Trial profile. HRQoL, health-related quality of life; PSA, prostate-specific antigen.
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Urinary HRQoL deteriorated 1 month after treatment and
improved within 1 year in both treatment arms. Bowel
HRQoL deteriorated less than five points from baseline in
both arms and remained at a similar level during follow-up.
Sexual activity in patients without hormonal therapy never
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FIG 2. Kaplan-Meier curves up to 7 years for (A) biochemical disease-free survival (bDFS) (P, .001), (B) disease-free survival (DFS) (P, .001), and (C)
distant metastases-free survival (DMFS) (P5 .26) comparing the standard treatment of 77 Gy in 35 fractions to the whole prostate with an additional focal
boost to the macroscopic visible tumor up to 95 Gy.
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DISCUSSION
The FLAME trial is the first phase III RCT showing that the
addition of a focal boost to the intraprostatic lesion(s) in EBRT
for prostate cancer significantly improves 5-year bDFS, from
85% in the standard arm to 92% in the focal boost arm.
Differences in toxicity were small and not statistically signifi-
cant. However, to adequately assess late GU (urethra-related)
toxicity longer follow-up is required. In the FLAME trial, a
urethra dose constraint was not used. However, such a
constraint was incorporated in our subsequent focal boost
studies. The comparable toxicity was achieved by strictly
respecting dose constraints to OARs, reducing the focal boost
dose if necessary. The 7% increase in bDFS therefore likely
underestimates the positive effect of focal boosting to 95 Gy
since a clear decrease in biochemical failure rate with in-
creasing boost dose was found. There was no significant
difference in PCSS and OS. The follow-up time was relatively
short to draw conclusions on survival for prostate cancer and
the study was not powered for these end points. Although
there was no significant difference in DMFS, the data suggest
a dose-response relation for distant metastatic failure. How-
ever, a longer follow-up is required to confirm this.
In contrast to previous trials, the FLAME trial was heavily
weighed to high-risk patients (84%). Nevertheless, bDFS in the
standard treatment arm was high compared with four whole-
gland dose-escalation RCTs including low-, intermediate-, and
high-risk patients, with five-year bDFS rates ranging from 64%
to 76.5% in the dose-escalation arms.2,4,6 In the MD Anderson
trial, a six-year freedom from failure of 70% was observed in
the dose-escalation arm.1 The high overall bDFS in the FLAME
trial is likely to be explained by improved disease staging before
treatment. Also, themild hypofractionation (2.2Gyper fraction)
in both arms resulted in a higher EQD2 of 81.8 Gy to the whole
prostate, compared with whole-gland dose-escalation trials.1–4
As in the FLAME trial biochemical recurrence started after 1
year, this might suggest that high-risk prostate cancer is not
necessarily metastasized at the time of diagnosis. The addition
of (neo)adjuvant hormonal therapy may play a role in delaying
biochemical failure, although 35% of the patients in both arms
did not receive hormonal therapy.
A BT boost is another strategy to increase the dose. The
ASCENDE-RT (Androgen Suppression Combined with Elective
Nodal andDose EscalatedRadiation Therapy) trial showed that
a whole-gland low-dose rate BT boost, combined with hor-
monal therapy, leads to an improved bDFS compared with
whole-gland EBRT.However, this cameat the cost of increased
5-year grade 3 GU toxicity.23,24 Our results suggest that the
same positive effect can be achieved without additional toxicity
by limiting the boost to the intraprostatic lesion(s). In the FLAME
trial, standard modern-day treatment planning techniques
such as intensity-modulated radiotherapy and volumetric
modulated arc therapy on conventional linear accelerators (with
on-board imaging) were used. Now that the concept of focal
boosting has been demonstrated to benefit bDFS, improved
EBRTplanning techniques14 or the use of a focal boost withBT,
such as investigated in the TARGET trial (ClinicalTrials.gov
identifier: NCT01802242),25 can be effective in depositing the
high-boost dose without exceeding OAR constraints.
In 2009 when the FLAME trial started, a 35-39 fractions
schedule was standard. Large randomized Phase III hypo-
fractionation trials, such as the CHHiP (conventional or
hypofractionated high dose intensity modulated radiotherapy
for prostate cancer) andHYPRO (HYpofractionated irradiation
for PROstate cancer) trials,26,27 showed that hypofractionated
EBRT in 2.4-3.4 Gy fractions is equivalent to conventionally
fractionated (1.8-2 Gy) EBRT. Around 2018 the schedule of
20 times 3Gy in 4-5 weeks (EQD2 78.8 Gy) became the new
standard.28 The results of the FLAME trial also indicate that the
current standard, moderately hypofractionated 20 times 3 Gy,
could be improved by (focal) dose escalation.
TABLE 2. Results of Cox Regression Analysis for Biochemical Disease-Free Survival (bDFS), Disease-Free Survival (DFS) and Distant Metastases-Free
Survival (DMFS) Unadjusted and Adjusted for Center, Age (y), Hormonal Treatment Duration (mo), Timing of Hormonal Treatment (Neoadjuvant v Adjuvant),
T-Stage, Initial PSA (ng/mL), and Gleason Score
bDFS DFS DMFS
HR 95% CI P HR 95% CI P HR 95% CI P
Unadjusted 0.46 0.30 to 0.72 , .001 0.50 0.33 to 0.75 , .001 0.75 0.45-1.24 .26
Adjusted 0.45 0.29 to 0.71 , .001 0.48 0.32 to 0.74 , .001 0.72 0.43-1.22 .22
Abbreviations: HR, hazard ratio; PSA, prostate-specific antigen.


































FIG 3. Predicted probability of biochemical failure up to 7 years as a
function of achieved dose to the gross tumor volume (D98%; Gy).
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A meta-analysis of randomized trials looking at dose-
response and fractionation sensitivity of prostate EBRT
indicated a shallow, but highly significant, dose-response
relationship.29 Although Vogelius et al. suggested saturation
might be present in the dose-effect at an EQD2 of. 80 Gy,
the FLAME trial (EQD2Gy 115.8 Gy with an a/b ratio of 1.2
Gy) and ASCENDE RT trial (50 Gy 1 115 Gy BT boost)
proved otherwise. Dose escalation will result in better
outcome; however, high doses are needed.
For low and intermediate prostate cancer the HYPO-RT-PC
(HYPOfractionatedRadioTherapy of intermediate risk localised
Prostate Cancer) trial showed that extreme hypofractionation is
noninferior to conventional fractionated radiotherapy in terms
of failure-free survival and late toxicity. Acute toxicity was equal
in PACE-B (intensity-modulated fractionated radiotherapy
versus stereotactic body radiotherapy for prostate cancer);
however, the HYPO-RT-PC showed more pronounced acute
toxicity.30,31 In 2018, the American Society for Radiation On-
cology (ASTRO), ASCO, and American Urological Association
(AUA) Evidence-Based Guidelines stated that extreme hypo-
fractionated 35 -36,25 Gy in five fractions may be offered to
patients with low- and intermediate-risk prostate cancer.28
However, this does not apply for high risk and most likely a
higher dose is needed. Several studies use focal dose esca-
lation with a boost of 38-50 Gy (ClinicalTrials.gov iden-
tifier: NCT01409473, NCT01856855, NCT02145494,
NCT01976962, NCT04245670, ISRCTN04483921,
NCT02254746, NCT04045717, NCT02853110). The
prospective phase II Hypo-FLAME trial investigated the
safety of the technique of the FLAME trial with extreme
hypofractionation.32 Mostly high-risk (75%) patients
were treated with 35 Gy in 5 weekly fractions to the
whole prostate gland with an integrated boost up to
50 Gy to the mpMRI-defined tumor(s). The technique
proved safe without severe acute GI or GU toxicity.
A limitation of the FLAME study wasmissing toxicity data, as
described previously.15 We do not expect this to have
influenced the late toxicity results. This is supported by an
equal number of missing data in both arms. Second, the
PI-RADS recommendations were published after the start
of the FLAME trial and GTV contouring guidelines were not
available for prostate cancer, resulting in interobserver
variability.16,33 Nonetheless, we did find a significant in-
crease in bDFS in the focal boost arm. Because of the
pragmatic and practice-based approach of the trial, each
center used its own OAR constraints. In addition, all centers
added the same high-dose constraint for the rectum and
bladder (D1cc rectum max 77 Gy and D1cc bladder max
80 Gy). As the study arms were stratified for center at
random assignment, center-specific constraints are not
likely to have influenced the comparison of the two study
arms.
An inherent limitation due to the long duration of follow-up
is the change in practice over time. The FLAME trial started
in 2009 and we used a pragmatic approach according to
clinical practice at the time. (Neo)adjuvant hormonal
therapy was given according to clinical practice. We did not
collect the percent-positive biopsies and were therefore not
able to calculate the University of California, San Francisco-
Cancer of the Prostate Risk Assessment (UCSF-CAPRA)
score.34 The International Society of Urologic Pathology35
score was implemented after patient inclusion in the
FLAME trial; in the FLAME trial only the Gleason sum score
was registered. Patients were staged according to clinical
practice, imaging with or without a subsequent lymph node
dissection. Most patients were included before a prostate-
specific membrane antigen-positron emission tomography
(PSMA-PET) scan was available. However, these limitations
were similar in both treatment arms and we do not believe
that it influenced our findings.
Strengths of our study are a large number of patients, the
multicenter collaboration, and the high treatment compli-
ance. PSA follow-up to assess the presence of bDFS was
carried out thoroughly with minimal missing data, and the
response rates of the HRQoL questionnaires were satisfy-
ing. Additionally, standard modern-day radiotherapy
techniques were used and no additional technology or
equipment was required. Thus, the implementation of a
focal boost strategy does not lead to additional costs.
Although there was no survival benefit observed until now,
the reduction of biochemical recurrence by 50% would
probably benefit patients and their QoL. Biochemical re-
currence means intensified follow-up and diagnostic ex-
aminations with associated anxiety and eventually
additional treatments with subsequent toxicity, especially
when this reduction in recurrence can be achieved without
impacting toxicity or HRQoL compared with standard
treatment and at no additional costs.
In conclusion, the FLAME trial showed that a focal boost to
a high dose improves bDFS in intermediate- and high-risk




P77 Gy 95 Gy Difference in % (95% CI) 77 Gy 95 Gy Difference in % (95% CI)
Grade $ 2 23.0 27.8 4.8 (22.3 to 12.0) .19 12.2 12.7 0.5 (25.0 to 5.9) .86
Grade $ 3 3.5 5.6 2.1 (21.3 to 5.6) .22 1.4 1.4 0 (21.9 to 2.0) .99
Abbreviation: GU, genitourinary.
aLate toxicity defined as toxicity from 3 months to 5 years after start of treatment.
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localized prostate cancer, without additional toxicity. Focal
dose escalation in (extreme) hypofractionated schedules
should be further explored. As we observed a clear dose-
response relation, further improvement of tumor control
may be feasible when more advanced techniques allow a
higher boost dose.
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